Transforming the immune environment in prostate cancer treatment
Converting Cold to Hot Tumor Microenvironment in Prostate Cancer by Targeting Chromatin Effector
This study is looking at how to make prostate cancer more responsive to immunotherapy by blocking a protein called PYGO2, which stops immune cells from fighting the cancer, with the hope that this will help improve treatment outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project ID | NIH-10817694 on NIH RePORTER |
What this research studies
This research investigates how to change the immune environment in prostate cancer to make it more responsive to immunotherapy. It focuses on a specific protein called PYGO2, which is believed to play a key role in preventing immune cells from attacking cancer cells. By using targeted inhibitors to block PYGO2, the researchers aim to enhance the infiltration of immune cells into tumors, potentially improving the effectiveness of existing cancer treatments. The study will explore the mechanisms behind this process and assess the impact of PYGO2 inhibition on cancer progression and treatment response.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic prostate cancer who have not responded to current immunotherapy treatments.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with advanced prostate cancer by making tumors more susceptible to immunotherapy.
How similar studies have performed: Other research has shown promise in targeting similar mechanisms in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Notre Dame, United States
- University of Notre Dame — Notre Dame, United States (Active)
Researchers
- Principal investigator: Lu, Xin — University of Notre Dame
- Study coordinator: Lu, Xin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.